Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Papillomavirus Infections 2Leiomyoma 2Inflammation 2Frailty 2Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Radiodermatitis 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Atypical Squamous Cells of the Cervix 1

Interventions

durvalumab 13Bevacizumab 11Nivolumab 10tremelimumab 7pembrolizumab 6lenvatinib 6fludarabine 6Cyclophosphamide 6atezolizumab 4Radiosurgery 4Cisplatin 4toripalimab 3relatlimab 3Magnetic Resonance Imaging 3Ipilimumab 3Gemcitabine 3X-Rays 2Standard of Care 2Sorafenib 2Riluzole 2Radiotherapy 2Photons 2Patient Navigation 2Lidocaine 2Hepatectomy 2Dexamethasone 2Biopsy 2trastuzumab deruxtecan 1tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × epigallocatechin gallate × 1 year × Clear all
NCT06015022 2025-09-05

CATCH-B

University of Texas Southwestern Medical Center

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡